NEW YORK--(BUSINESS WIRE)--
The Klein Law Firm announces the commencement of an investigation of Ohr Pharmaceutical, Inc. (OHRP) concerning possible violations of federal securities laws.
On January 5, 2018, Ohr Pharmaceutical announced topline data from its MAKO study to evaluate the use of Squalamine combination therapy for the treatment of wet-AMD. Ohr Pharmaceutical announced the MAKO study did not meet its primary efficacy endpoint. Following this news, shares of Ohr Pharmaceutical fell from a close of $2.02 on January 4, 2018, to a close of $0.38 on January 5, 2018.
If you suffered a loss in Ohr Pharmaceutical and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kkclasslaw.com/OHRP-Info-Request-Form-264.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.